Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential.
Xiaoya WeiJiacong GaoDandan ZhouCongjuan XuPing ChenShuiping ChenYanhong ZhangXuehua LiuGuanxian LiGuangbo ZhuHuimin LiuJinjin LiBin GengLinlin GaoZhihui ChengIain L LamontDaniel PletzerYongxin JinShouguang JinWeihui WuPublished in: Antimicrobial agents and chemotherapy (2024)
Murepavadin is a peptidomimetic that specifically targets the lipopolysaccharide transport protein LptD of Pseudomonas aeruginosa . Here, we found that murepavadin enhances the bactericidal efficacies of tobramycin and amikacin. We further demonstrated that murepavadin enhances bacterial respiration activity and subsequent membrane potential, which promotes intracellular uptake of aminoglycoside antibiotics. In addition, the murepavadin-amikacin combination displayed a synergistic bactericidal effect in a murine pneumonia model.
Keyphrases
- pseudomonas aeruginosa
- cystic fibrosis
- acinetobacter baumannii
- biofilm formation
- human health
- inflammatory response
- toll like receptor
- risk assessment
- protein protein
- reactive oxygen species
- cancer therapy
- escherichia coli
- staphylococcus aureus
- candida albicans
- climate change
- intensive care unit
- mechanical ventilation
- respiratory failure